CN108697641A - 临床制剂 - Google Patents

临床制剂 Download PDF

Info

Publication number
CN108697641A
CN108697641A CN201680059201.6A CN201680059201A CN108697641A CN 108697641 A CN108697641 A CN 108697641A CN 201680059201 A CN201680059201 A CN 201680059201A CN 108697641 A CN108697641 A CN 108697641A
Authority
CN
China
Prior art keywords
solution
cells
cell
certain embodiments
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680059201.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·盖伊
J·拉特利夫
R·E·索思威克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Ocata Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocata Therapeutics Inc filed Critical Ocata Therapeutics Inc
Priority to CN202411047354.1A priority Critical patent/CN119112939A/zh
Publication of CN108697641A publication Critical patent/CN108697641A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dentistry (AREA)
  • Reproductive Health (AREA)
CN201680059201.6A 2015-08-18 2016-08-18 临床制剂 Pending CN108697641A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411047354.1A CN119112939A (zh) 2015-08-18 2016-08-18 临床制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18
US62/206,821 2015-08-18
PCT/US2016/047545 WO2017031312A1 (en) 2015-08-18 2016-08-18 Clinical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411047354.1A Division CN119112939A (zh) 2015-08-18 2016-08-18 临床制剂

Publications (1)

Publication Number Publication Date
CN108697641A true CN108697641A (zh) 2018-10-23

Family

ID=56843032

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680059201.6A Pending CN108697641A (zh) 2015-08-18 2016-08-18 临床制剂
CN202411047354.1A Pending CN119112939A (zh) 2015-08-18 2016-08-18 临床制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411047354.1A Pending CN119112939A (zh) 2015-08-18 2016-08-18 临床制剂

Country Status (15)

Country Link
US (4) US11013808B2 (enExample)
EP (1) EP3334415A1 (enExample)
JP (3) JP7043392B2 (enExample)
KR (3) KR20230058544A (enExample)
CN (2) CN108697641A (enExample)
AU (2) AU2016308818B2 (enExample)
BR (1) BR112018003031B1 (enExample)
EA (2) EA202190722A1 (enExample)
HK (1) HK1256839A1 (enExample)
IL (3) IL299326A (enExample)
MX (2) MX2018002038A (enExample)
PH (1) PH12018500371B1 (enExample)
SG (1) SG10201913250SA (enExample)
TW (3) TWI833293B (enExample)
WO (1) WO2017031312A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
IL305070B2 (en) 2014-12-30 2025-11-01 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
ES2980659T3 (es) 2015-03-23 2024-10-02 Astellas Inst For Regenerative Medicine Ensayos mejorados de potencia de células de epitelio pigmentario retiniano (EPR) humano y progenitores de fotorreceptores
SG10201913250SA (en) * 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
WO2018003908A1 (ja) * 2016-06-30 2018-01-04 株式会社ヘリオス 移植用媒体
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
CN111741735A (zh) * 2017-12-29 2020-10-02 细胞治疗神经科学有限公司 视网膜色素上皮细胞组合物
CA3151637A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Methods of treating vascular diseases
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
BR112022006644A2 (pt) 2019-10-30 2022-07-12 Astellas Inst For Regenerative Medicine Métodos para a produção de células epiteliais de pigmento da retina
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
CN117915772A (zh) * 2021-07-15 2024-04-19 二氧化硅医疗产品公司 用于核酸和生物样品的防腐剂组合物及其使用方法
WO2023176906A1 (ja) * 2022-03-16 2023-09-21 住友ファーマ株式会社 移植用媒体
US20250257321A1 (en) 2022-07-18 2025-08-14 Astellas Institute For Regenerative Medicine Methods of treating brain injury
TW202417614A (zh) 2022-08-23 2024-05-01 安斯泰來再生醫藥協會 用於治療眼部病症的感光救援細胞（prc）組成物及方法
JPWO2024172043A1 (enExample) * 2023-02-14 2024-08-22
WO2025122978A1 (en) * 2023-12-06 2025-06-12 Bluerock Therapeutics Lp Cell cryopreservation and delivery vehicle and methods of using the same
FR3158633A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible comprenant des éléments cellulaires hétérogènes
FR3158635A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible particulière comprenant des éléments cellulaires hétérogènes utile pour l’administration de thérapies cellulaires
WO2025158058A1 (fr) * 2024-01-26 2025-07-31 Treefrog Therapeutics Composition biocompatible comprenant des elements cellulaires heterogenes
WO2025204688A1 (ja) * 2024-03-26 2025-10-02 株式会社ダイセル リン脂質膜保護用液体組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562188A1 (en) * 1992-03-27 1993-09-29 Chung-Ho Chen Composition for tissues to sustain viability and biological functions in surgery and storage
EP0781547A1 (en) * 1995-12-22 1997-07-02 Chemedica S.A. Sodium hyaluronate based ophthalmic formulation for use in eye surgery
US20030216431A1 (en) * 2002-05-17 2003-11-20 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2014095953A1 (en) * 2012-12-18 2014-06-26 Gambro Lundia Ab Dialysis composition

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
ATE199626T1 (de) 1993-06-04 2001-03-15 Biotime Inc Plasma-artige lösung
US6399110B1 (en) 1997-08-22 2002-06-04 Shimizu Pharmaceutical Co., Ltd. Glucose-containing preparation
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
EP1247526B1 (en) 2000-01-11 2005-12-14 Ophtecs Corporation Perfusion liquid preparations for ophthalmic operations
AU2005207042B2 (en) 2004-01-23 2010-09-09 President And Fellows Of Harvard College Improved modalities for the treatment of degenerative diseases of the retina
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
KR102651433B1 (ko) 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
JP2010500047A (ja) 2006-08-15 2010-01-07 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 間葉系幹細胞馴化培地
CN104946591A (zh) 2007-10-12 2015-09-30 奥卡塔治疗公司 制备rpe 细胞和rpe 细胞的组合物的改良方法
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
EP2712921B1 (en) 2008-05-06 2018-07-11 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
EP2501802A4 (en) 2009-11-17 2013-08-21 Advanced Cell Tech Inc METHOD FOR PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS FROM HUMAN RPE CELLS
KR20180086301A (ko) 2009-12-04 2018-07-30 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
BR112012014104A2 (pt) 2009-12-04 2016-07-05 Stem Cell & Regenerative Medicine International Inc método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco
AU2011280878B2 (en) 2010-07-23 2016-06-16 Astellas Institute For Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
IL287381B2 (en) 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
RS57886B1 (sr) 2011-11-30 2019-01-31 Astellas Inst For Regenerative Medicine Mezenhimalne stromalne ćelije i primene vezane za njih
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CA3178138A1 (en) 2011-12-06 2013-06-13 Astellas Institute For Regenerative Medicine Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
CN103783031B (zh) 2012-10-29 2015-11-18 四川新生命干细胞科技股份有限公司 一种细胞保存液
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
KR102527507B1 (ko) 2013-03-15 2023-04-28 아스텔라스 인스티튜트 포 리제너러티브 메디슨 만능 줄기 세포로부터 제조된 광수용기 및 광수용기 전구체
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
JP6778181B2 (ja) 2014-09-05 2020-10-28 アステラス インスティテュート フォー リジェネレイティブ メディシン 網膜神経節細胞およびその前駆体
ES2980659T3 (es) 2015-03-23 2024-10-02 Astellas Inst For Regenerative Medicine Ensayos mejorados de potencia de células de epitelio pigmentario retiniano (EPR) humano y progenitores de fotorreceptores
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
CA3151637A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Methods of treating vascular diseases
BR112022006644A2 (pt) 2019-10-30 2022-07-12 Astellas Inst For Regenerative Medicine Métodos para a produção de células epiteliais de pigmento da retina
CA3216719A1 (en) 2021-05-03 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562188A1 (en) * 1992-03-27 1993-09-29 Chung-Ho Chen Composition for tissues to sustain viability and biological functions in surgery and storage
EP0781547A1 (en) * 1995-12-22 1997-07-02 Chemedica S.A. Sodium hyaluronate based ophthalmic formulation for use in eye surgery
US20030216431A1 (en) * 2002-05-17 2003-11-20 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2014095953A1 (en) * 2012-12-18 2014-06-26 Gambro Lundia Ab Dialysis composition

Also Published As

Publication number Publication date
TWI833293B (zh) 2024-02-21
MX2018002038A (es) 2018-07-06
AU2022206757B2 (en) 2024-09-05
US20260053930A1 (en) 2026-02-26
US20190030168A1 (en) 2019-01-31
JP2022040140A (ja) 2022-03-10
EA037915B1 (ru) 2021-06-07
PH12018500371A1 (en) 2018-08-29
US20240350639A1 (en) 2024-10-24
AU2022206757A1 (en) 2022-08-18
IL299326A (en) 2023-02-01
US11013808B2 (en) 2021-05-25
US12419958B2 (en) 2025-09-23
US11957754B2 (en) 2024-04-16
EA202190722A1 (ru) 2021-10-29
IL291163B1 (en) 2023-01-01
EP3334415A1 (en) 2018-06-20
CN119112939A (zh) 2024-12-13
JP7449915B2 (ja) 2024-03-14
HK1256839A1 (zh) 2019-10-04
BR112018003031B1 (pt) 2023-12-26
TWI915731B (zh) 2026-02-21
TW201717912A (zh) 2017-06-01
EA201890516A1 (ru) 2018-09-28
NZ740608A (en) 2023-09-29
KR102411018B1 (ko) 2022-06-20
TW202245816A (zh) 2022-12-01
SG10201913250SA (en) 2020-03-30
TWI772270B (zh) 2022-08-01
BR112018003031A2 (pt) 2018-09-18
US20190358330A9 (en) 2019-11-28
CA2995977A1 (en) 2017-02-23
AU2016308818A1 (en) 2018-04-05
IL291163B2 (en) 2023-05-01
WO2017031312A1 (en) 2017-02-23
AU2016308818B2 (en) 2022-04-21
JP7043392B2 (ja) 2022-03-29
IL257551A (en) 2018-04-30
KR20220090583A (ko) 2022-06-29
KR20180048722A (ko) 2018-05-10
MX2022010363A (es) 2022-09-21
KR102651291B1 (ko) 2024-03-26
IL257551B (en) 2022-04-01
US20210275673A1 (en) 2021-09-09
JP2018523682A (ja) 2018-08-23
KR20230058544A (ko) 2023-05-03
PH12018500371B1 (en) 2023-01-20
IL291163A (en) 2022-05-01
JP2024074803A (ja) 2024-05-31
TW202417023A (zh) 2024-05-01

Similar Documents

Publication Publication Date Title
US12419958B2 (en) Clinical formulations
KR102073730B1 (ko) 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
KR102054904B1 (ko) 인간 ｒｐｅ 세포의 약제학적 제제 및 그의 용도
CN108578789A (zh) 眼科粘弹剂
US20260043008A1 (en) Cell cryopreservative formulations and methods of use
CA2995977C (en) Clinical formulations
US20210220515A1 (en) Viscoelastic agent material
EA047097B1 (ru) Клинические композиции
NZ740608B2 (en) Clinical formulations
WO2022025240A1 (ja) 角膜内皮細胞を保存するための方法および容器

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181023

RJ01 Rejection of invention patent application after publication